10-Q: Reviva Pharmaceuticals Reports Q3 2024 Results, Cites Ongoing Clinical Trials and Recent Financings

Reviva Pharmaceuticals' Q3 2024 report highlights a net loss, ongoing clinical trials for brilaroxazine, and recent capital raises to support operations.

Summary

• Reviva Pharmaceuticals reported a net loss of $8.4 million for the three months ended September 30, 2024, and a net loss of $23.7 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents stood at $5.6 million as of September 30, 2024, with a working capital deficit of approximately $10.7 million.
• Research and development expenses were $6.9 million for the quarter and $18.2 million for the nine-month period, primarily related to the clinical development of brilaroxazine.
• The company completed a registered direct offering in May 2024, raising $2.8 million, and an underwritten offering in August 2024, raising $3.1 million, net of expenses.
• Reviva is progressing with its clinical trials for brilaroxazine, including the OLE trial with topline data expected in December 2024, and plans to initiate the RECOVER-2 trial in Q1 2025.
• The company has identified material weaknesses in its internal controls over financial reporting and clinical trial expenses and is working to remediate them.
• The company's current cash on hand is not sufficient to satisfy its operating cash needs for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical trial results and recent financings, the company's financial position is weak, with significant losses, a working capital deficit, and concerns about its ability to continue as a going concern. The material weaknesses in internal controls also raise concerns.

Positives

• The company successfully completed the RECOVER-1 trial for brilaroxazine, showing statistically significant results.
• The company has made progress in its ongoing OLE trial, with 108 patients completing 12 months of treatment.
• The company has secured additional funding through registered direct and underwritten offerings in May and August 2024.
• The FDA has agreed that the RECOVER-2 trial can be conducted as a 4-week study, which may accelerate the timeline.

Negatives

• The company reported a significant net loss for both the quarter and the nine-month period.
• The company has a working capital deficit of approximately $10.7 million.
• The company's current cash on hand is not sufficient to satisfy its operating cash needs for the next 12 months.
• The company has identified material weaknesses in its internal controls over financial reporting and clinical trial expenses.
• The company's accumulated deficit is $158.0 million.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash to meet operating needs for the next 12 months.
• The company may not be able to secure additional funding on acceptable terms, or at all.
• The company's clinical trials may not be successful, and regulatory approvals may not be granted.
• The company's internal control weaknesses could lead to further financial misstatements or compliance issues.
• The company is subject to risks inherent in a clinical-stage company, including dependence on medical acceptance of the product, regulatory approvals, and competition.

Future Outlook

The company expects to incur significant expenses and increased operating losses for the next several years as it continues to develop its product candidates. The company plans to complete the OLE trial, initiate the RECOVER-2 trial, and submit an NDA for brilaroxazine in the second quarter of 2026, subject to additional financing.

Management Comments

• Management believes that the company has adequate cash on hand to cover anticipated outlays into the end of the fourth quarter of 2024.
• Management has commenced procedures to remediate the material weaknesses in internal controls.
• Management expects research and development expenses to increase as the company advances its development programs.

Industry Context

The company operates in the competitive pharmaceutical industry, focusing on central nervous system, inflammatory, and cardiometabolic diseases. The development of new therapies in these areas is subject to significant regulatory and clinical risks. The company's focus on brilaroxazine for schizophrenia aligns with the need for new treatments in this area, but the company faces competition from other pharmaceutical companies developing similar therapies.

Comparison to Industry Standards

• The company's cash burn rate and net losses are typical for a clinical-stage pharmaceutical company, but the company's cash position is weaker than some of its peers.
• The company's reliance on external funding is common in the industry, but the company's ability to secure additional funding is uncertain.
• The company's clinical trial results for brilaroxazine are promising, but the company still needs to complete additional trials and obtain regulatory approvals.
• The company's identification of material weaknesses in internal controls is a concern, but the company is taking steps to remediate them.
• Compared to companies like Karuna Therapeutics (KRTX) and Acadia Pharmaceuticals (ACAD), which also focus on CNS disorders, Reviva is at an earlier stage of development and has a smaller market capitalization. Karuna has a market cap of over $6 billion and has an approved drug, while Acadia has a market cap of over $3 billion and several approved products. Reviva's market cap is under $100 million and it has no approved products.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional funding.
• Employees may be affected by potential cost-cutting measures or changes in the company's operations.
• Customers (potential patients) may benefit from the development of new therapies, but the timeline for availability is uncertain.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company plans to report topline data from its OLE Trial in December 2024.
• The company plans to initiate the registrational RECOVER-2 Trial in Q1 2025.
• The company plans to submit an NDA for brilaroxazine in the second quarter of 2026.
• The company will continue to seek additional funding to support its operations.

Key Dates

Keywords

brilaroxazine, clinical trials, schizophrenia, RECOVER-1, RECOVER-2, OLE Trial, financial results, capital raise, warrants, pharmaceuticals, research and development, net loss, internal controls